Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
PDX1258 | Alpelisib | PI3Ka | PI3K/mTOR | 17.8572 | 0.6307 | 0.0589 | 0.0069 | 0.7348 | 79.6392 | 0.9089 |
PDX1258 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.99608 | 0.1062 | 0.2777 | 0.0362 | 0.6747 | 1.3027 | 0.98871 |
PDX1258 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9970 | -0.0328 | 0.0026 | 0.0000 | Inf | -2.2747 |
PDX1258 | Buparlisib | pan PI3K | PI3K/mTOR | 1.3631 | -0.3924 | 0.2516 | 0.0862 | 1.2064 | 2.8058 | 0.99443 |
PDX1258 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.035598 | -0.2066 | 0.3637 | 0.0836 | 1.5171 | 0.041875 | 0.98779 |
PDX1258 | A-1210477 | Mcl-1 | Misc | Inf | 0.9187 | -0.0034 | 0.0025 | 2.4151 | 15.1662 | 0.71902 |
PDX1258 | Olaparib | PARP | Misc | 11.9912 | 0.5770 | 0.0287 | 0.0113 | 1.2287 | 29.2905 | 0.94883 |
PDX1258 | Luminespib | HSP90 | Misc | 0.01007 | -0.2899 | 0.6101 | 0.1943 | 5.0000 | 0.011049 | 0.99799 |
PDX1258 | ABT-737 | Bcl2/XL | Misc | Inf | 0.7580 | 0.0124 | 0.0237 | 0.9162 | 13.677 | 0.78603 |
PDX1258 | Vorinostat | HDAC | Misc | 1.5746 | -0.0232 | 0.2113 | 0.0249 | 1.3725 | 1.8225 | 0.99287 |
PDX1258 | Bleomycin | Radiation | Misc | 0.78329 | 0.0721 | 0.2946 | 0.0937 | 0.8662 | 0.88979 | 0.99416 |
PDX1258 | Saracatinib | SRC | MAPK/nRTK | 0.7252 | 0.1837 | 0.2770 | 0.0370 | 0.8198 | 0.50742 | 0.98008 |
PDX1258 | Etoposide | Topo II | Chemotherapy | 0.31701 | -0.1807 | 0.3942 | 0.1360 | 1.0906 | 0.41876 | 0.99346 |
PDX1258 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.021598 | -0.1339 | 0.7143 | 0.0924 | 1.3176 | 0.024774 | 0.99367 |
PDX1258 | Topotecan | Topo I | Chemotherapy | 0.013472 | -0.4565 | 0.8673 | 0.2817 | 0.8122 | 0.026852 | 0.98013 |
PDX1258 | Ipatasertib | AKT | PI3K/mTOR | 4.4024 | 0.3985 | 0.1556 | 0.0120 | 0.7553 | 1.2185 | 0.94717 |
PDX1258 | Doxorubicin | Chemo | Chemotherapy | 0.0091389 | -0.4928 | 0.7540 | 0.2368 | 1.1844 | 0.013938 | 0.97567 |
PDX1258 | Taxol | Chemo | Chemotherapy | 0.0021522 | -0.0818 | 0.6797 | 0.2357 | 1.2501 | 0.0022935 | 0.98829 |
PDX1258 | Volasertib | PLK | Cell cycle | 0.0073734 | -0.2320 | 0.5602 | 0.1765 | 1.8198 | 0.0083258 | 0.98847 |
PDX1258 | Cisplatin | Chemo | Chemotherapy | 2.5568 | 0.3181 | 0.1555 | 0.0433 | 1.6027 | 1.5449 | 0.99079 |
PDX1258 | Dinaciclib | pan CDK | Cell cycle | 0.011566 | -0.6173 | 0.7036 | 0.2838 | 3.5943 | 0.014366 | 0.99779 |
PDX1258 | AZD7762 | CHK1/2 | Cell cycle | 0.014946 | -0.4528 | 0.9199 | 0.3234 | 1.6838 | 0.021221 | 0.99249 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
MDA-MB-468 | Tivantinib | MET | RTK | 0.30706 | -0.4549 | 0.4903 | 0.2341 | 2.9835 | 0.37002 | 0.99499 |
MDA-MB-468 | Cabozantinib | VEGFR2/MET | RTK | 8.9681 | 0.4233 | 0.0441 | 0.0115 | 1.7711 | 16.6732 | 0.9812 |